Data Sheet 1_Clinical outcomes of pembrolizumab plus gemcitabine and cisplatin in a Japanese institutional subgroup of KEYNOTE-966: a dexamethasone-minimizing supportive-care approach.docx

We performed multivariable analysis using the Cox regression hazard model and inverse-probability weighting propensity score (IPW) analysis to adjust for between-group background differences.</p>Results<p>It was found that there were 22 and 16 patients in the Pembrolizumab+GC and Placebo+GC groups, respectively. The hazard ratios (HRs) of overall survival (OS) and progression-free survival (PFS) for the Pembrolizumab+GC group were 0.622 (95% confidence interval [CI], 0.318–1.217) and 0.360 (95% CI, 0.178–0.728), respectively; the objective response rates were 31.8% and 6.3%, respectively.

The HR for OS and PFS in the multivariable and IPW analyses were numerically similar to those in the original analysis, which was better than that observed in the entire KEYNOTE-966 cohort.</p>Discussion<p>Our experience of Pembrolizumab + GC over Placebo +GC generates a clinical question whether the efficacy of Pembrolizumab may be enhanced when antibiotics and antiemetic DEX are avoided.</p>